SCHEMBL5397403

SCHEMBL5397403

Cc1cccc(-c2cnc(N)nc2-c2c[nH]c(C(=O)N3CC=C(c4ccc(F)cc4)CC3)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.46
PARP1 P09874 2/20 0.39
LIMK1 P53667 3/20 0.38
LIMK2 P53671 3/20 0.38
RPS6KA3 P51812 1/20 0.37
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 2/20 0.36
NPC1 O15118 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
CASP3 P42574 1/20 0.36
RAB9A P51151 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
JAK1 P23458 1/20 0.36
CCNT1 O60563 1/20 0.36
CDK9 P50750 1/20 0.36
NAMPT P43490 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5396722 0.92 ADORA1 (0.50) ADORA1PARP1ALDH1A1SMN1; SMN2MAPT
SCHEMBL5392823 0.91 MAPK1 (0.46) ADORA1PARP1LIMK1LIMK2ALDH1A1
SCHEMBL5401741 0.88 ADORA1 (0.46) ADORA1CCNT1CDK9
SCHEMBL5397011 0.82 ADORA1 (0.53) ADORA1MAPK1MAPK10
SCHEMBL5410578 0.82 MAPK1 (0.54) ADORA1ALDH1A1MAPTNPC1HPGD
SCHEMBL5403894 0.81 ADORA1 (0.52) ADORA1MAPK1MAPK10
SCHEMBL5401294 0.81 ADORA1 (0.52) ADORA1RAB9AMAPK1MAPK10
SCHEMBL5407239 0.80 ALDH1A1 (0.49) ADORA1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL5406975 0.79 ADORA1 (0.49) ADORA1MAPK1MAPK10
SCHEMBL5412680 0.79 ADORA1 (0.54) ADORA1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363906-B1 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMA (US) 2015-07-15 EP claimed
US-6743791-B2 ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS VERTEX PHARMACEUTICALS INCORPORATED 2004-06-01 US claimed
US-20030092714-A1 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2003-05-15 US claimed
EP-1363906-B1 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMA (US) 2015-07-15 EP disclosed
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof CAO JINGRONG 2007-11-15 US disclosed
US-7253187-B2 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-07 US disclosed
US-20040229875-A1 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAPKAPK2 ADORA1 4421/4885PARP1 1324/4885LIMK1 1695/4885
US-20040229875-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAP2K2 ADORA1 4106/4885PARP1 451/4885LIMK1 1408/4885
US-20030092714-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAP2K2 ADORA1 4106/4885PARP1 451/4885LIMK1 1408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.